Ipeleng Kgosiemang-Xaba | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Ipeleng Kgosiemang-Xaba
University of the Free State, South Africa
Ipeleng Kgosiemang-Xaba
Affiliation University of the Free State
Country South Africa
Scopus ID 56707418000
Documents 9
Citations 241
h-index 7
Subject Area Oncology
Event Health Scientists Awards

Ipeleng Kgosiemang-Xaba is presented in this academic recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions.[1]

Abstract

Ipeleng Kgosiemang-Xaba is presented in this recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions. The profile therefore highlights an interdisciplinary trajectory centered on biologically active South African plants, cancer-related mechanisms, and translational opportunities while maintaining a neutral distinction between documented scientific outputs and award recognition.[3]

Keywords

Euphorbia species; cancer; medicinal plants; pharmacological properties; toxicity; secondary metabolites; breast cancer; antiproliferative activity; iron oxide nanoparticles; iron dioxide nanoparticles; natural-product pharmacology; phytochemicals. These terms are aligned particularly with the publication literature addressing Southern African Euphorbia species and experimental anticancer research.[2]

Introduction

Ipeleng Kgosiemang-Xaba’s research profile reflects an interdisciplinary interest in oncology, medicinal plants, pharmacology, and biomedical technology. Her publications address Euphorbia-derived bioactive compounds and experimental anticancer approaches, including nanoparticle systems evaluated against breast cancer cell lines. These themes place natural-product research within a framework of cancer research and translational biomedical investigation.[1]

Research Profile

Ipeleng Kgosiemang-Xaba has published work spanning molecular biology, medicinal plants, phytochemistry, pharmacology, and oncology. Her research includes studies of Euphorbia species and their secondary metabolites, together with experimental investigations of antiproliferative effects and nanoparticle-mediated approaches. The available literature indicates a continuing interest in linking biological resources with therapeutic research questions.[2][3]

Research Contributions

Ipeleng Kgosiemang-Xaba’s contributions include systematic examination of Southern African Euphorbia species, their medicinal uses, toxicity, phytochemical constituents, and reported pharmacological activities. Her research also includes green synthesis of iron-based nanoparticles using Euphorbia tirucalli and evaluation of antiproliferative activity against breast cancer cell lines, thereby connecting plant science with experimental oncology.[2][3]

Publications

Ipeleng Kgosiemang-Xaba is associated with publications addressing Euphorbia pharmacology, anticancer research, nanoparticle synthesis, and molecular biology. A 2025 review in Plants examined medicinal uses, toxicity, secondary metabolites, and pharmacological properties of Southern African Euphorbia species, while a 2023 Journal of Experimental Nanoscience article evaluated iron-based nanoparticles and breast cancer models.[5]

Research Impact

Ipeleng Kgosiemang-Xaba’s research impact can be considered through the relevance of her publications to natural-product pharmacology, cancer biology, and biomedical nanotechnology. Her work contributes evidence on underexplored Southern African plant resources and experimental anticancer strategies. Citation activity and publication visibility provide measurable indicators, while broader clinical significance requires further validation.[3]

Award Suitability

Ipeleng Kgosiemang-Xaba’s documented research themes are compatible with an Innovative Research Award focused on oncology, natural-product discovery, and biomedical technology. Her publications demonstrate research activity involving anticancer constituents, Euphorbia species, phytochemicals, and nanoparticle systems. Award suitability should remain subject to the event’s published formal criteria, independent verification, and comparative assessment.[4]

Conclusion

Ipeleng Kgosiemang-Xaba presents a research profile connecting Southern African medicinal plants with pharmacology, nanotechnology, and oncology. Her publications provide evidence of work on Euphorbia chemistry, toxicity, antiproliferative activity, and cancer-oriented experimental systems. Collectively, these outputs support recognition of an emerging interdisciplinary research direction without implying clinical efficacy beyond published evidence.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ipeleng Kgosiemang-Xaba, Author ID 56707418000. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56707418000
  2. Kgosiemang, I. K. R., Lefojane, R., Adegoke, A. M., Ogunyemi, O., Mashele, S. S., & Sekhoacha, M. P. (2025). Pharmacological significance, medicinal use, and toxicity of extracted and isolated compounds from Euphorbia species found in Southern Africa: A review. Plants, 14(3), 469.https://doi.org/10.3390/plants14030469
  3. Kgosiemang, I. K. R., Adegoke, A. M., Mashele, S. S., & Sekhoacha, M. P. (2023). Green synthesis of iron oxide and iron dioxide nanoparticles using Euphorbia tirucalli: Characterization and antiproliferative evaluation against three breast cancer cell lines. Journal of Experimental Nanoscience, 18(1), 2276276.https://doi.org/10.1080/17458080.2023.2276276
  4. Parvez, M., Qhanya, L. B., Mthakathi, N. T., Kgosiemang, I. K. R., et al. (2016). Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: Special focus on mycobacterial P450s. Scientific Reports, 6, 33099.https://doi.org/10.1038/srep33099
  5. Kgosiemang, I. K. R. (2024). Targeted delivery of iron, cobalt and magnesium nanoparticles incorporating anticancer constituents of Euphorbia species for treatment of breast cancer. Doctor of Health Sciences in Biomedical Technology, Central University of Technology, Free State.https://cutscholar.cut.ac.za/items/e527142e-a8dc-4c94-8eb1-121facf1eff7/full

Rasha Elsabagh | Oncology | Research Excellence Award

Published on by Health Scientists

Dr. Rasha Elsabagh | Oncology | Research Excellence Award

Researcher | Animal Health Research Institute(AHRI) | Egypt

Rasha H. Elsabagh is a multidisciplinary immunology specialist and cancer stem cell researcher with extensive expertise spanning stem cell biology, immuno-oncology, translational cancer research, and veterinary biomedical sciences. She currently serves as a researcher at the Animal Health Research Institute, where her work integrates advanced immunological diagnostics, molecular biology, and national livestock immunization programs that directly contribute to animal health surveillance and disease control. Her academic training culminated in a doctoral degree in cancer immunology from Cairo University, where her research focused on circulating cancer stem cells and photothermal nanotherapy as predictive and monitoring tools for tumor response. She has conducted advanced international research training at University of California San Francisco, gaining high-level proficiency in flow cytometry, immunofluorescence, and human stem cell analysis, and later expanded her translational oncology experience as a visiting research fellow at the Cancer Institute of Montpellier, working on nanoparticle-mediated RNA delivery to tumor-infiltrating immune cells. Her scientific output includes multiple peer-reviewed publications in high-impact journals and international conference proceedings, with her work receiving sustained scholarly citations and global academic recognition. Her research collaborations span institutions in North America, Europe, and the Middle East, reflecting her active role in international scientific networks in stem cell biology, cancer immunology, and nanomedicine. Beyond laboratory research, she contributes to national capacity building through scientific training, quality assurance in diagnostic immunology, and public health–oriented animal disease control programs. Her work has direct societal impact through improvements in cancer diagnostics, advancement of immunotherapeutic strategies, and strengthening of zoonotic disease surveillance, positioning her as a globally engaged scientist at the intersection of experimental research, translational medicine, and public health. She has 2 citations from 2 documents with an h-index of 1.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Xiao, T., Eze, U. C., Charruyer-Reinwald, A., Weisenberger, T., Khalifa, A., … (2024). Short cell cycle duration is a phenotype of human epidermal stem cells. Stem Cell Research & Therapy, 15(1), 76.

2. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Ragab, E., … (2021). Quantitative flow cytometry assessment of feline circulatory breast cancer stem cells. Advances in Animal and Veterinary Sciences, 9(12), 2201–2215.

3. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H. H., Ragab, E., … (2025). Gold nano-rod (AuNR)-mediated plasmonic photothermal therapy in feline mammary carcinoma: Assessing metastatic and nonmetastatic outcomes. Veterinary Oncology, 2(1), 33.

4. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H., Ragab, E., … (2022). Prevention of in situ recurrence and distant metastasis in feline mammary carcinoma treated with plasmonic photothermal therapy.

 

Sipping Kemegne Marius Tresor | Pharmacology | Best Researcher Award

Published on by Health Scientists

Dr. Sipping Kemegne Marius Tresor | Pharmacology | Best Researcher Award

Research scholar | Slovak Academy of Sciences | Slovakia

Dr. Sipping Kemegne Marius Tresor is a biochemist and postdoctoral research fellow whose expertise spans immunopharmacology, cancer biology, inflammatory diseases, and phytomedicine, with a focus on natural bioactive compounds and their translational therapeutic applications. Trained at leading institutions across Africa and Europe, he has developed a strong multidisciplinary foundation integrating molecular biology, pharmacology, biotechnology, and clinical research principles to advance innovation in precision therapeutics. His research has pioneered the exploration and characterization of polysaccharide-rich bioactive fractions from medicinal fungi, particularly Ganoderma species, elucidating their antioxidant, anti-inflammatory, and anti-metastatic potentials and offering promising chemopreventive and therapeutic leads for cancer and immune-mediated disorders. His scientific contributions include peer-reviewed publications in internationally indexed journals and authorship of a scholarly book, demonstrating sustained commitment to advancing biomedical knowledge and global research excellence. Dr. Sipping’s work has been strengthened through impactful collaborations across Africa, Europe, and Asia with prominent scientists and international research groups, fostering interdisciplinary partnerships and capacity building in natural product research and immunotherapeutics. His ongoing investigations focus on isolating novel polysaccharides and developing nanotechnology-enabled drug delivery systems to enhance therapeutic efficacy against chronic inflammatory conditions, such as rheumatoid arthritis, bridging traditional bioresources with cutting-edge biomedical strategies. Beyond laboratory research, he is a certified clinical research professional committed to strengthening translational pathways from preclinical discovery to potential clinical application. His membership in distinguished scientific bodies reflects his dedication to contributing to the global research community. Driven by the vision to harness bioresources and advanced biotechnology for improved public health, Dr. Sipping aims to deliver innovative, accessible, and safe therapeutic options addressing cancer, autoimmune, and infectious diseases, thereby contributing to scientific progress and societal well-being. He has 81 citations from 9 documents with an h-index of 5.

Profiles:  Scopus | ORCID

Featured Publications

1. Sipping, M., Thakur, D., Singh, B., Njamen, D., & Mukherjee, S. (2025). Polysaccharide extract of Ganoderma resinaceum restricts breast cancer progression in vitro by intervening in epithelial–mesenchymal transition and cancer stemness. Revista Brasileira de Farmacognosia.

2. Sipping, M., Sathish Kumar, T., & Kamdem, N. (2025). Scientific investigation on antibacterial, antioxidant, cytotoxic effects and TLC bioautography of Terminalia schimperiania stem bark extracts. Journal of Complementary and Integrative Medicine.

3. Kamga Silihe, K., Defo Mbou, W., Ngo Pambe, J. C., Kenmogne, L. V., Fotso Maptouom, L., Kemegne Sipping, M. T., Zingue, S., & Njamen, D. (2023). Comparative anticancer effects of Annona muricata Linn (Annonaceae) leaves and fruits on DMBA-induced breast cancer in female rats. BMC Complementary Medicine and Therapies.

4. Nana Tchoupang, E., Yadji, V., Wangbara, J. B., Kemegne Sipping, M. T., Zingue, S., Njamen, D., & Mutalik, S. (2022). In vitro and in vivo antiproliferative actions of Solanum gilo Raddi (Solanaceae) fruit extract on breast tissues. Advances in Pharmacological and Pharmaceutical Sciences.

5. Kamga Silihe, K., Zingue, S., Kemegne Sipping, M. T., Busuioc Cazanevscaia, A., Dediu Botezatu, A. V., Njamen, D., & Dinica, R. M. (2022). The antioxidant potential of Ficus umbellata Vahl (Moraceae) that accelerates in vitro and in vivo anti-inflammatory protective effects. Applied Sciences.

Nayeralsadat Fatemi | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Nayeralsadat Fatemi | Oncology | Best Researcher Award 

Researcher | Research Institute for Gastroenterology and Liver Diseases | Iran

Dr. Nayeralsadat Fatemi is a distinguished Research Scientist at the Research Institute for Gastroenterology and Liver Diseases (RIGLD), Tehran, Iran, with a profound background in genetics and molecular medicine. She obtained her B.Sc. in Genetics from Esfahan University in 2007, followed by an M.Sc. in Genetics from Shahrekord University in 2012, and earned her Ph.D. in Molecular Medicine from Zanjan University of Medical Sciences in 2020. Dr. Fatemi’s research primarily focuses on colorectal cancer, gastrointestinal disorders, reproductive genetics, and the interplay between microbiota and cancer-related molecular pathways. Her work integrates genomics, transcriptomics, and bioinformatics analyses to uncover biomarkers, drug resistance mechanisms, and potential therapeutic targets. She has contributed to over thirty peer-reviewed publications in high-impact journals, including Gut Pathogens, Virulence, Expert Reviews in Molecular Medicine, Digestive Diseases and Sciences, and International Journal of Cancer, with notable studies on Fusobacterium nucleatum in colorectal cancer, microRNA-mediated regulatory networks, and genetic causes of recurrent pregnancy loss. Dr. Fatemi has presented her findings at numerous national and international conferences, earning recognition for excellence in research communication, including Best Poster awards at reproductive medicine congresses. Beyond her research contributions, she serves as an active reviewer and editorial board member for several scientific journals in molecular medicine, cancer biology, and reproductive genetics, reflecting her commitment to advancing scientific rigor and knowledge dissemination in health sciences. Her career exemplifies a dedication to translational research, bridging fundamental molecular discoveries with clinical applications to improve diagnostics, therapeutics, and patient outcomes in gastroenterology and reproductive medicine. She has 218 citations from 31 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Fatemi, N., Tierling, S., Es, H. A., Varkiani, M., Mojarad, E. N., Aghdaei, H. A., … (2022). DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine.

2. Fatemi, N., Sanati, M. H., Shamsara, M., Moayer, F., Zavarehei, M. J., Pouya, A., … (2014). TBHP-induced oxidative stress alters microRNAs expression in mouse testis. Journal of Assisted Reproduction and Genetics.

3. Amiri Yekta, A., Dalman, A., Eftekhari-Yazdi, P., Sanati, M. H., Shahverdi, A. H., … (2013). Production of transgenic goats expressing human coagulation factor IX in the mammary glands after nuclear transfer using transfected fetal fibroblast cells.

4. Fatemi, N., Sanati, M. H., Jamali Zavarehei, M., Ayat, H., Esmaeili, V., … (2013). Effect of tertiary‐butyl hydroperoxide (TBHP)‐induced oxidative stress on mice sperm quality and testis histopathology.

5. Rejali, L., Seifollahi Asl, R., Sanjabi, F., Fatemi, N., Asadzadeh Aghdaei, H., … (2023). Principles of molecular utility for CMS classification in colorectal cancer management.

Yang Zhang | Clinical Medicine | Best Researcher Award

Published on by Health Scientists

Prof. Dr. Yang Zhang | Clinical Medicine | Best Researcher Award 

Director | Department of Laboratory Medicine Chongqing University | China

Dr. Yang Zhang, Ph.D., currently serves as Director of the Department of Laboratory Medicine at Chongqing University Affiliated Renji Hospital and is an Associate Chief Physician, Postdoctoral Fellow in Clinical Laboratory Diagnostics, and doctoral and master’s supervisor at Chongqing University. She earned her Bachelor of Medicine in Laboratory Medicine (2008), Master of Medicine in Clinical Laboratory Diagnostics (2011), and Ph.D. in Clinical Laboratory Diagnostics (2015) from the Third Military Medical University, complemented by a Ministry of Education-sponsored visiting scholarship at Loma Linda University, USA (2012–2015). Her research centers on precision molecular diagnostics in oncology, with a special focus on POCT rapid diagnostic reagents and spectroscopy-based label-free diagnostic techniques. Dr. Zhang has led multiple high-level research projects, including three funded by the National Natural Science Foundation of China, one by the National Key R&D Program, and numerous provincial and military projects, securing over 6.88 million RMB in funding. She has published more than 40 academic papers as first or corresponding author, with 15 SCI-indexed articles, an H-index of 24, and a single paper cited over 280 times. Her scholarly contributions extend to 12 Chinese invention patents, 1 international PCT patent, and five co-edited scientific monographs, including works on molecular diagnostics and terahertz applications. Dr. Zhang’s achievements have been recognized with numerous honors, such as Chongqing High-Level Young Medical Talent (2022), the “Top Ten Young Scientists in Shapingba District” (2022), First Prize in the Chongqing Association for Science and Technology Innovation (2023), and the National Laboratory Medicine Science and Technology Innovation Award (2021). She also serves as a reviewer for the NSFC and contributes to several national professional committees in laboratory medicine. She has 1044 citations from 43 documents with an h-index of 16.

Profile: Scopus | ORCID 

Publications

1. Zhang, Y. (2020). ENT1 inhibition attenuates apoptosis by activation of cAMP/pCREB/Bcl2 pathway after MCAO in rats. Experimental Neurology, 331, 113362.

2. Zhang, Y. (2020). Identification of immune-related prognostic biomarkers based on the tumor microenvironment in 20 malignant tumor types with poor prognosis. Frontiers in Oncology, 10, 1008.

3. Tian, H., Yuan, C., Liu, Y., Xia, K., Li, M., Xie, F., Chen, Q., Chen, M., Fu, W., & Zhang, Y. (2020, July 28). A sample-to-answer quantification platform for point-of-care testing of circulating microRNAs based on allosteric spherical nanoprobe. Preprint.

4. Zhang, Y. (2020). Evaluation of the reliability of six commercial SERS substrates. Plasmonics, 15(5), 1323–1332.

5. Zhang, Y. (2020). Dataset concerning plasmonic thermal destruction of murine melanoma by gold nanoparticles obtained by green chemistry. Data in Brief, 30, 105370.